Tag: Medical Research
-
Proteios Technology, Inc. Awarded $1.6 Million NIH SBIR Grant to Commercialize its Multivariate Cell Isolation Technology
SEATTLE, Wash. — Proteios Technology, Inc. is pleased to announce it’s received a $1.6 million SBIR Phase II grant from the National Institutes of Health (NIH) to commercialize its multivariate (parallel) cell isolation technology. Grant funds will be used to extend Proteios’ cell isolation kits to include up to 20 of the most common cell…
-
Oral Vaccine Boosts COVID Immunity: study conducted on nonhuman primates is published in the journal Vaccine
ROCHESTER, Minn. — Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine.
-
Myrio Therapeutics and Pure MHC, LLC Announce Research Collaboration to Develop Novel, Targeted Antibody-Based Cancer Therapies
OKLAHOMA CITY, Okla. — Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC’s proprietary offering of MHC peptide targets for oncology with Myrio’s revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based…
-
Neurosoft Bioelectronics Receives Nearly $3 Million in Funding
NEW YORK, N.Y. — Neurosoft Bioelectronics, an early-stage company developing tools for unmet needs in epilepsy and tinnitus, was awarded nearly $3 million USD, from the SERI-Funded European Innovation Council Accelerator Grant and a share of the $165,000 USD through the European Research Council Proof-of-Concept Grant.
-
November Is C. difficile Awareness Month With An Annual Conference, Recognizing Subject Matter Experts, Expressing Gratitude to US Governors
TAMPA, Fla. — C Diff Foundation announced today that the 9th Annual International C. diff. Conference and Health EXPO welcomed over 40 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, and academia on November 4-5, 2021. World-renowned presenters delivered data and discussed critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile with global…
-
Kalyagen™ Announces Registration of STEMREGEN® in Spain, CEO at Madrid Stem Cell Symposium
AUSTIN, Texas — Kalyagen is pleased to announce the successful product registration of STEMREGEN® in Spain. This announcement coincides with Christian Drapeau’s, CEO and Chief Scientist of Kalyagen, trip to Madrid, Spain last week to speak at the IV Jornadas Internacionales Otto H. Warburg symposium at the NH Madrid Príncipe de Vergara.
-
Drink HRW Hydrogen Tablets Improve Markers of Aging in the Elderly
COQUITIAM, B.C. — Aging is a reality that we all deal with, with age-related diseases creating a massive burden on our healthcare system. Now, Drink HRW reports that a new randomized, placebo controlled clinical trial that followed elderly participants for 6 months, published online October 1st in Experimental Gerontology, explains that high doses of hydrogen…
-
COVID Variants Do Not Stop C. diff. Awareness Walks Worldwide
TEANECK, N.J. — C Diff Foundation announced today that the 5th Annual Global C. diff. Awareness Walks will take place on-demand, on a livestream, and in-person at Sims Park, New Port Richey, FL, and Brown Street Park Complex, Spring city, PA, and Milton A. Votee, Teaneck, NJ. This year’s annual events will take place on…